Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update

Glaukos ( (GKOS) ) has issued an update.

Glaukos Corporation released an investor presentation in March 2026 outlining its strategy to transform glaucoma and keratoconus care through interventional, dropless therapies and to build durable new markets in ophthalmology. The company emphasized its expansion from traditional topical eye drops toward procedural and device-enabled pharmaceutical solutions that reduce patient compliance burdens and broaden access to effective care.

A central focus of the presentation was iDose TR, a long-duration travoprost implant designed to deliver up to three years of intraocular pressure reduction for open-angle glaucoma and ocular hypertension patients, which had been approved by the U.S. FDA for re-administration in January 2026. Glaukos reported strong clinical and real-world indicators for iDose TR, including high rates of freedom from topical medications at 12 months and favorable safety, and detailed a pipeline of next-generation iDose platforms and interventional glaucoma products intended to extend treatment duration, streamline administration and reinforce its leadership in the emerging interventional glaucoma paradigm.

The company also framed two major unmet clinical needs—non-compliance with topical glaucoma drops and gaps in keratoconus diagnosis and treatment access—as long-term growth drivers for its interventional model. By investing heavily in R&D, advancing multiple late-stage clinical programs and promoting procedure-based therapies that shift control from patients to physicians, Glaukos signaled its ambition to solidify its competitive position and influence evolving standards of care in the ophthalmic market.

The most recent analyst rating on (GKOS) stock is a Hold with a $126.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.

Spark’s Take on GKOS Stock

According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.

The score is held back primarily by weak financial performance (margin compression, widening losses, and negative cash flow). Offsetting this, the technical setup is constructive (clear uptrend with positive momentum) and the latest earnings call was supportive with reaffirmed >20% growth guidance and strong iDose TR/Epioxa progress, though execution and reimbursement/coding timing risks remain.

To see Spark’s full report on GKOS stock, click here.

More about Glaukos

Glaukos Corporation is a hybrid pharmaceutical-device company focused on innovative treatments for chronic eye diseases, particularly glaucoma and corneal disorders such as keratoconus. The company positions itself as a pioneer in interventional glaucoma and interventional keratoconus, offering dropless, procedure-based therapies that aim to improve outcomes and quality of life for large and underserved patient populations.

Glaukos has built a portfolio of 12 commercialized products and 13 disclosed pipeline programs targeting conditions including ocular hypertension, open-angle glaucoma, keratoconus, blepharitis, myopia and retinal diseases. It highlights strong historical growth, significant R&D investment since 2018 and an industry-leading pipeline as key elements of its strategy to create durable new markets and lead paradigm shifts in ophthalmic care.

Average Trading Volume: 783,218

Technical Sentiment Signal: Strong Buy

Current Market Cap: $6.99B

Learn more about GKOS stock on TipRanks’ Stock Analysis page.